Compare Charles River Laboratories Intl. Inc (CRL) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs NRG Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while NRG Energy Inc trades at $138.77 (market cap $29.19B). The key difference: NRG Energy Inc is far larger — about 2.6× Charles River Laboratories Intl. Inc's market cap, and NRG Energy Inc pays a 1.37% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NRG | |
|---|---|---|
Market Cap | $11.14B | $29.19B |
Sector | Health | Utilities |
52-Week High | $233.60 | $184.03 |
52-Week Low | $145.57 | $120.65 |
Enterprise Value | $14.00B | $53.02B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
NRG Energy trades at $139.48, down 0.67% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 153.27 but attractive P/S of 0.86, while revenue grew to $30.71B in 2025. Analyst sentiment remains positive with 64% buy ratings, though technical indicators suggest near-term pressure with support at $138.
Outlook is cautiously optimistic given strong analyst support and dividend payments, but risks include high debt levels and volatile cash flows. Investors should weigh solid revenue growth against margin compression and elevated valuation multiples before positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
